(Q34206318)

31 July 2017

1 reference

title

Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem? (English)

1 reference

31 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

1 reference

Sanne I

1

1 reference

31 July 2017

Smego RA Jr

series ordinal

2

1 reference

31 July 2017

Mendelow BV

series ordinal

3

1 reference

31 July 2017

publication date

1 January 2001

1 reference

International Journal of Infectious Diseases

31 July 2017

published in

1 reference

31 July 2017

volume

5

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

43-48

1 reference

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

Long-term suppression of HIV-1 by hydroxyurea and didanosine

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

Hydroxyurea and HIV-1 viraemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

Macrophages as a source of HIV during opportunistic infections

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2801%2990048-7

7 January 2021

10.1016/S1201-9712(01)90048-7

Identifiers

DOI

1 reference

31 July 2017

1 reference